Growth hormone release during sleep in growth-retarded children with normal response to pharmacological tests

E. CACCIARI, G. COCCAGNA, A. CICOGNANI, P. PIRAZZOLI, R. GALLASSI, P. FARNETI, F. BERNARDI, F. ZAPPULLA, G. GOBBI, AND P. VERUCCHI

From the Departments of Paediatrics, Neurology, and Anaesthesiology, University of Bologna, Italy

SUMMARY Twenty-one prepubertal children of small stature, 10 boys and 11 girls, aged from 4·3 to 12·8 years, were studied. Their height was <3rd centile, and during the preceding year all had a growth rate <4·5 cm/year. Arginine and L-dopa tests were given, and the release of growth hormone (GH) during monitored sleep was investigated. On the basis of the electroencephalogram and horizontal electro-oculogram, sleep was divided into stages 1–2–3–4 and rapid-eye-movement. All the children had a GH response >8 ng/ml in at least one of the two pharmacological tests, and were therefore accepted as not suffering from GH deficiency.

In all 21 children during sleep there was at least one secretory peak with GH >8 ng/ml. Of a total of 46 secretory peaks recorded, 22 (48%) took place during deep, slow sleep (stages 3–4), 10 (22%) during light sleep (stage 2), 10 (22%) during REM sleep, and 4 (8%) during wakening. In 4 patients (19%) no secretory peak was observed during stages 3–4, even though there were peaks at other times.

The data (a) show that it is essential to monitor GH throughout the night to ascertain with certainty the presence or absence of physiological secretory peaks of GH; (b) emphasise the rare disagreement between pharmacological and physiological tests; (c) suggest the use of this physiological test for GH secretion in those cases where the insulin test may be hazardous.

The secretion of some hormones, especially growth hormone (GH) and prolactin, is closely linked to the sleep-waking cycle, and the secretion rate of GH is highest during sleep (Alford et al., 1973). The spontaneous release of this hormone by the pituitary in the sleeping patient and its relationship with the various stages of sleep have been the object of several studies in both the adult and child (Takahashi et al., 1968; Parker et al., 1969; Sassin et al., 1969; Illig et al., 1970; Underwood et al., 1971; Mace et al., 1972), but has been little exploited for investigating growth-retarded children (Eastman and Lazarus, 1973; Wise et al., 1975). In some cases of growth retardation a normal response to pharmacological testing has been associated with a lack of normal secretion during sleep (Eastman and Lazarus, 1973; Wise et al., 1975).

In a group of growth-retarded children we studied the pattern of GH secretion in relation to the various stages of sleep, correlating results with plasma GH levels after arginine and L-dopa stimulation, and with growth rates.

Materials and methods

Twenty-one prepubertal children (10 boys, 11 girls), aged from 4·3 years to 12·8 years, were studied. Their heights were <3rd centile (Tanner et al., 1966) and growth rate in the 12 months preceding the study was <4·5 cm/year (mean 4·08 ± 0·48 SD, range 2·4–5 cm).

The children were in good health and receiving no treatment. Arginine and L-dopa tests were carried out by methods already described (Cicognani et al., 1975). Before and during the study of GH secretion during sleep, the children continued to lead a normal life. For blood sampling a flexible cannula was inserted into an antecubital vein 1 hour before sleep; it was connected to a plastic tube with a 3-way tap, and with a slow drip of saline. On the basis of
the electroencephalogram and the horizontal electrooculogram, sleep was divided into stages (1-2-3-4) and REM (rapid-eye-movement), according to standardised criteria (Rechtschaffen and Kales, 1968).

Blood samples for GH were collected before sleep, on the following morning after wakening, and at various times during the night dependent on the sleep stage, but at least every 20 minutes. Samples were also taken at 10 am, 2 pm, and 6 pm on the day of the test. The children were fully informed about the details of the procedure which they accepted well. They all slept for adequate periods and had at least 3 complete sleep cycles.

Plasma GH was measured by the double-antibody radioimmunoassay method (Molinatti et al., 1969). During sleep GH peaks >8 ng/ml were accepted as secretary. This value was chosen because in our experience peaks higher than this recorded during various pharmacological tests are indicative of normal GH release.

Statistical analysis of results was carried out with Student's t test and calculating the correlation coefficient. The peak obtained during the two pharmacological tests and its relationship with the highest peak obtained during sleep was considered. The number of peaks during the night and their time in relation to the sleep stages were also evaluated. Finally, the percentage retardation of bone age in comparison with chronological age, and growth rate in cm/year during the 6 months preceding the study were correlated with the maximum GH peaks observed during the pharmacological tests and during sleep.

Results

All children who had a GH response >8 ng/ml in at least one of the two pharmacological tests were considered as not being GH deficient (Cacciari et al., 1976). Of the 21 patients (62%) who had GH peaks >8 ng/ml during both the pharmacological tests, the remaining 8 cases (38%) in only one of the tests. 3 children (14%) did not respond to the arginine test, and 5 (24%) did not respond to the L-dopa test.

The mean (±SD) maximum GH peak of the arginine test was 11·4 ± 6·5 ng/ml, and that of the L-dopa was 16·2 ± 4·6 ng/ml. The mean (±SD) plasma GH levels at 10 am, 2 pm, and 6 pm on the same day of the sleep monitoring were 1·3 ± 0·8, 2·5 ± 0·6, and 2·0 ± 1·9 ng/ml, respectively. The mean values obtained before the beginning of the test and after its end were 2·1 ± 1·4 and 1·5 ± 0·8 ng/ml. The difference between these plasma levels was not significant.

In all children who underwent the test there was at least one GH secretory peak during sleep. The mean maximum peak during sleep was 18·3 ± 6·5, which was higher (P<0·025) than that obtained in the same group of children during the arginine test, but not significantly different from that obtained during the L-dopa test. The mean maximum peak attained during sleep in the children who had responded normally to both pharmacological tests was 19·2 ± 5·6 ng/ml, and it did not differ from the value (17·1 ± 5·4) found in the patients who had responded to only one of the two stimuli.

GH pattern during sleep is shown in the Table. Most of the secretory peaks took place during slow, deep sleep (stage 3-4) (48%) and in the first sleep cycle (52%). 20 patients out of 21 (95%) had at least one secretory peak during the first sleep cycle. During the sleep cycles following the first the secretory peaks were more uniformly distributed in all the sleep stages. Of the peaks during the waking period, two were in the phase that precedes sleep, one during the morning wakening, and one during a night wakening after a short period of sleep during which the slow deep stages of sleep were omitted. In 4 patients (19%) no secretory peak was observed during stage 3-4, even though the peaks were present in other stages; in these cases the peak followed stage 3-4 by 8, 14, 14, and 24 minutes, respectively.

Table. Total number of secretory peaks and incidence of the highest secretory peak in the different sleep stages and sleep cycles (21 subjects)

<table>
<thead>
<tr>
<th>No. of secretory peaks</th>
<th>1st sleep cycle</th>
<th>2nd sleep cycle</th>
<th>3rd sleep cycle and following</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wakening</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Stage 1-2</td>
<td>2</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Stage 3-4</td>
<td>17</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>REM</td>
<td>2</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Total</td>
<td>24 (52%)</td>
<td>9 (19%)</td>
<td>13 (28%)</td>
</tr>
<tr>
<td>Highest secretory peak</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wakening</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Stage 1-2</td>
<td>11</td>
<td>1</td>
<td>12 (57%)</td>
</tr>
<tr>
<td>Stage 3-4</td>
<td>1</td>
<td>2</td>
<td>6 (28%)</td>
</tr>
<tr>
<td>REM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>13 (62%)</td>
<td>5 (24%)</td>
<td>3 (14%)</td>
</tr>
</tbody>
</table>

During the whole night the highest secretory peak occurred in most of the patients during stage 3-4 (57%), and/or during the first sleep cycle (62%). In 2 children the secretory peak lasted 3 hours and 2½ hours respectively, thus occupying more than one stage and more than one sleep cycle.

There was no correlation between the GH peak obtained during the arginine and L-dopa tests and the maximum peak obtained during sleep, nor between the GH values found during the day and the
Discussion

This study has confirmed that sleep is an important physiological stimulus for the release of GH in children. Whereas 14% and 24% of the children examined did not respond to arginine and l-dopa respectively, during sleep there was in all the children at least one secretory peak of GH > 8 ng/ml, which in pharmacological tests we have found to indicate normal release of GH; furthermore, the mean maximum peak obtained during sleep was higher than that obtained during the arginine test.

Since it has been pointed out that each individual has his own characteristic sleep rhythm and night GH release rate (Parker et al., 1969), we may suppose that the repetition of a certain endocrinological pattern influences the growth rate.

Under our experimental conditions there was no correlation between the night secretion of GH and growth rate and retardation of bone development. Nor did the tonic secretion of GH during the daytime correlate with the night secretion of the same hormone. On the other hand, none of our cases showed disagreement between the results of the pharmacological tests and the sleep test, both types of test providing evidence of normal GH release.

We consider that polygraphic monitoring of a growth-retarded child in order to collect a single blood sample at a pre-determined moment during sleep (Mace et al., 1972; Alford et al., 1973; Eastman and Lazarus, 1973; Wise et al., 1975) is not a very useful diagnostic approach. Had we adopted it, we should have had a high percentage of false-negative results, because of the very variable night release rates of GH. In only 57% of our cases was there a peak in the first stage 3–4 of sleep (Fig.), which is generally taken as a point of reference.

In conclusion, our data (a) confirm that maximum GH release takes place during the night; (b) show that it is essential to monitor GH throughout the night to ascertain with certainty the presence or absence of physiological secretory peaks of GH; (c) emphasise the rare disagreement between pharmacological and physiological tests for GH secretion; (d) suggest the use of this physiological test (night secretion of GH) in those cases where the insulin test may be hazardous.

References


Correspondence to Professor E. Cacciari, Clinica Pediatrica dell'Università, Via Massarenti 11, 40138 Bologna, Italy.

The following articles will appear in future issues of this journal:

Changing concepts in asthma. A. D. Milner.

Antigen handling by the gut. W. A. Walker

At what age do bronchodilator drugs work? W. Lenney and A. D. Milner.


Percutaneous catheterisation of the radial artery in newborn babies using transillumination. R. G. Pearse.